106 related articles for article (PubMed ID: 21967019)
1. Olmesartan medoxomil treatment is associated with decreased plasma B-type natriuretic peptide levels in patients on hemodialysis.
Suzuki R; Honda H; Niikura K; Akizawa T
Clin Exp Hypertens; 2012; 34(2):125-31. PubMed ID: 21967019
[TBL] [Abstract][Full Text] [Related]
2. Effects of olmesartan medoxomil, an angiotensin II type 1 receptor antagonist, on plasma concentration of B-type natriuretic peptide, in hypertensive patients with type 2 diabetes mellitus: a preliminary, observational, open-label study.
Kawai T; Takei I; Shimada A; Hirata T; Tanaka K; Saisho Y; Irie J; Horimai C; Matsumoto H; Itoh H
Clin Drug Investig; 2011; 31(4):237-45. PubMed ID: 21184621
[TBL] [Abstract][Full Text] [Related]
3. Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients.
Honda H; Hosaka N; Aoshima Y; Hirai Y; Michihata T; Akizawa T
Clin Exp Hypertens; 2012; 34(1):17-23. PubMed ID: 22149003
[TBL] [Abstract][Full Text] [Related]
4. Daily dialyses decrease plasma levels of brain natriuretic peptide (BNP), a biomarker of left ventricular dysfunction.
Odar-Cederlöf I; Bjellerup P; Williams A; Blagg CR; Twardowski Z; Ting G; Kjellstrand CM
Hemodial Int; 2006 Oct; 10(4):394-8. PubMed ID: 17014518
[TBL] [Abstract][Full Text] [Related]
5. Plasma B-type natriuretic peptide in dialyzed patients: marker of cardiovascular disease or link to plasma refilling.
De Mauri A; Bellomo G; Navino C; David P; Chiarinotti D; Capurro F; Brustia M; De Maria M; Ruva CE; Ciardi L; De Leo M
J Nephrol; 2011; 24(4):507-14. PubMed ID: 21240867
[TBL] [Abstract][Full Text] [Related]
6. Effects of aliskiren on blood pressure and humoral factors in hypertensive hemodialysis patients previously on angiotensin II receptor antagonists.
Ito T; Ishikawa E; Fujimoto N; Okubo S; Ito G; Ichikawa T; Nomura S; Ito M
Clin Exp Hypertens; 2014; 36(7):497-502. PubMed ID: 24433061
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension.
Tsutamoto T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
Hypertens Res; 2010 Feb; 33(2):118-22. PubMed ID: 19927151
[TBL] [Abstract][Full Text] [Related]
8. Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease.
Nishikimi T; Futoo Y; Tamano K; Takahashi M; Suzuki T; Minami J; Honda T; Uetake S; Asakawa H; Kobayashi N; Horinaka S; Ishimitsu T; Matsuoka H
Am J Kidney Dis; 2001 Jun; 37(6):1201-8. PubMed ID: 11382689
[TBL] [Abstract][Full Text] [Related]
9. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients.
Racek J; Králová H; Trefil L; Rajdl D; Eiselt J
Nephron Clin Pract; 2006; 103(4):c162-72. PubMed ID: 16645318
[TBL] [Abstract][Full Text] [Related]
10. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
[TBL] [Abstract][Full Text] [Related]
11. The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes.
Pugsley MK
Proc West Pharmacol Soc; 2005; 48():35-8. PubMed ID: 16416656
[TBL] [Abstract][Full Text] [Related]
12. Fluid overload correction and cardiac history influence brain natriuretic peptide evolution in incident haemodialysis patients.
Chazot C; Vo-Van C; Zaoui E; Vanel T; Hurot JM; Lorriaux C; Mayor B; Deleaval P; Jean G
Nephrol Dial Transplant; 2011 Aug; 26(8):2630-4. PubMed ID: 21273234
[TBL] [Abstract][Full Text] [Related]
13. Urinary angiotensin-converting enzyme 2 increases in diabetic nephropathy by angiotensin II type 1 receptor blocker olmesartan.
Abe M; Oikawa O; Okada K; Soma M
J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):159-64. PubMed ID: 25287898
[TBL] [Abstract][Full Text] [Related]
14. The plasma level of brain natriuretic peptide is increased in malnourished hemodialysis patients.
Chazot C; Jean G; Vo-Van C; Collonge C; Terrat JC; Vanel T; Lorriaux C; Hurot JM; Charra B
Blood Purif; 2009; 28(3):187-92. PubMed ID: 19648737
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
Chrysant SG; Chavanu KJ; Xu J
Am J Cardiovasc Drugs; 2009; 9(4):241-51. PubMed ID: 19655819
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics.
Tanaka H; Nagasawa Y; Matsui I; Hamano T; Iwatani H; Kawada N; Horio M; Ito T; Isaka Y; Imai E
Clin Exp Nephrol; 2009 Feb; 13(1):61-5. PubMed ID: 18574553
[TBL] [Abstract][Full Text] [Related]
18. Effect of telmisartan on ambulatory blood pressure monitoring, plasma brain natriuretic peptide, and oxidative status of serum albumin in hemodialysis patients.
Shimada H; Kitamura K; Anraku M; Miyoshi T; Adachi M; Tuyen DG; Wakamatsu S; Nonoguchi H; Tanaka M; Tomita K
Hypertens Res; 2005 Dec; 28(12):987-94. PubMed ID: 16671338
[TBL] [Abstract][Full Text] [Related]
19. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes.
Fliser D; Wagner KK; Loos A; Tsikas D; Haller H
J Am Soc Nephrol; 2005 Apr; 16(4):1135-40. PubMed ID: 15716329
[TBL] [Abstract][Full Text] [Related]
20. Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial.
Iseki K; Arima H; Kohagura K; Komiya I; Ueda S; Tokuyama K; Shiohira Y; Uehara H; Toma S;
Nephrol Dial Transplant; 2013 Jun; 28(6):1579-89. PubMed ID: 23355629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
